{
    "clinical_study": {
        "@rank": "36924", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Other", 
                "description": "Placebo 1250mg/m2 tablet by mouth every 12 hours for 14 days"
            }, 
            {
                "arm_group_label": "Capecitabine", 
                "arm_group_type": "Experimental", 
                "description": "Capecitabine 1250mg/m2 tablet by mouth every 12 hours for 14 days"
            }
        ], 
        "brief_summary": {
            "textblock": "Colorectal cancer patients with metastases (mCRC) at response under first-line chemotherapy\n      are candidates for an convenient maintenance treatment."
        }, 
        "brief_title": "Maintenance Chemotherapy for Metastatic Colorectal Carcinoma and Biological Marker", 
        "condition": "Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Colorectal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Colorectal cancer is one of the most common malignant tumors, with the morbidity of\n      approximate 100 million cases per year. About 40% of patients present with metastatic (stage\n      IV) colorectal cancer at the time of diagnosis, and about 25% of patients with local lesion\n      will ultimately develop metastatic disease.Therefore, our study is designed to investigate\n      that colorectal cancer patients with metastases (mCRC) at response under first-line\n      chemotherapy are candidates for an convenient maintenance treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - Age between 18 and 75 years Eastern Cooperative Oncology Group performance status (ECOG\n        PS) 0-1 histologically confirmed colorectal cancer with inoperable locally advanced or\n        recurrent and/or metastatic disease Life expectancy of at least 3 months Intact organ\n        function, including complete blood counts (CBC) showing normal values or any toxicity\n        limited to grade 1 and blood chemistry (SMA) showing liver and renal functions < 1.5 upper\n        normal limit (UNL).\n\n        Patients who achieved objective response or stable disease after 16-24 weeks first line\n        chemotherapy Signed informed consent\n\n        Exclusion Criteria:\n\n        - Known hypersensitivity to capecitabine Concurrent any other cancer (except BCC or\n        squamous cell carcinoma of skin). Inability to adhere to monthly visits to the oncology\n        unit for evaluation. Presence of brain metastases. Previous radiotherapy to the only site\n        of measurable disease. Evidence of severe or uncontrolled systemic disease No previous\n        chemotherapy for metastatic disease Positive serum pregnancy test in women of childbearing\n        potential unresolved bowel obstruction or malabsorption syndrome"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02043821", 
            "org_study_id": "20140116"
        }, 
        "intervention": [
            {
                "arm_group_label": "Capecitabine", 
                "description": "14days", 
                "intervention_name": "Capecitabine", 
                "intervention_type": "Drug", 
                "other_name": "Capecitabine"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "14 days", 
                "intervention_name": "placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Capecitabine", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 23, 2014", 
        "number_of_arms": "2", 
        "official_title": "Maintenance Chemotherapy for Metastatic Colorectal Carcinoma", 
        "other_outcome": {
            "description": "Adverse events and laboratory tests graded according to the NCI-CTC AE Version 4.", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "overall_contact": {
            "email": "yd15yt88@163.com", 
            "last_name": "Dong Yan, PhD", 
            "phone": "13621308215"
        }, 
        "overall_official": {
            "affiliation": "Beijing Chao Yang Hospital", 
            "last_name": "Guangyu An, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "progression-free survival of first-line chemotherapy with second-line chemotherapy", 
            "measure": "DDC:Duration of Disease Control", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02043821"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Beijing Chao Yang Hospital", 
            "investigator_full_name": "Dong Yan", 
            "investigator_title": "Beijing Chao Yang Hospital", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "measured from the initiation of chemotherapy to the date of the last follow-up or death", 
                "measure": "OS:Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "This is defined as the occurrence of either a confirmed complete (CR),a partial  response(PR)or stable disease(SD) as determined by the RECIST criteria from confirmed radiographic evaluations of target and non-target lesions.", 
                "measure": "DCR:Disease Control Rate", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Beijing Chao Yang Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beijing Chao Yang Hospital", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}